Cost comparison of F(ab')₂ and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis.

IF 1.8 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-02-12 DOI:10.1080/14737167.2025.2462236

Walter Garcia-Ubbelohde, Lia Pizzicato, Keith J Boesen, Swapna Munnangi, Liucheng Shi, Nicholas B Hurst, Mitchell DeKoven

{"title":"Cost comparison of F(ab')2 and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis.","authors":"Walter Garcia-Ubbelohde, Lia Pizzicato, Keith J Boesen, Swapna Munnangi, Liucheng Shi, Nicholas B Hurst, Mitchell DeKoven","doi":"10.1080/14737167.2025.2462236","DOIUrl":null,"url":null,"abstract":"Background: This study compared healthcare resource utilization (HCRU) and cost among patients treated for pit viper envenomation with Fab or F(ab')2 antivenom in the United States.Research design and methods: Patients administered Fab or F(ab')2 between January 2019 and September 2022 were identified from IQVIA's New Data Warehouse and placed into two mutually exclusive cohorts. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline differences between cohorts. All-cause HCRU and cost were assessed in the 6-months following antivenom administration (post-index) and compared between IPTW-adjusted cohorts.Results: In total, 242 and 98 patients receiving Fab and F(ab')2 were identified, respectively. Pre-IPTW adjustment, cohorts differed on demographics and select comorbidities (standardized mean difference [SMD] ≥0.10). Post-IPTW, most variables were balanced (SMD < 0.01). Post-index total (Fab: $70,994; F(ab')2: $55,324), medical ($69,162; $52,339), and inpatient costs ($49,466; $29,730) were higher among Fab than F(ab')2 patients (all p < 0.05). After multivariable adjustment, the total (cost ratio [CR]: 0.83; 95% confidence interval [CI]: 0.70-0.98), inpatient (CR: 0.63; 95% CI: 0.51-0.79), and inpatient pharmacy costs (CR: 0.48; 95% CI: 0.33-0.68) were lower in the F(ab')2 than Fab cohort.Conclusions: Patients administered Fab had higher post-index total, inpatient, and inpatient pharmacy costs than patients administered F(ab')2 AV.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.8000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2462236","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study compared healthcare resource utilization (HCRU) and cost among patients treated for pit viper envenomation with Fab or F(ab')₂ antivenom in the United States.

Research design and methods: Patients administered Fab or F(ab')₂ between January 2019 and September 2022 were identified from IQVIA's New Data Warehouse and placed into two mutually exclusive cohorts. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline differences between cohorts. All-cause HCRU and cost were assessed in the 6-months following antivenom administration (post-index) and compared between IPTW-adjusted cohorts.

Results: In total, 242 and 98 patients receiving Fab and F(ab')₂ were identified, respectively. Pre-IPTW adjustment, cohorts differed on demographics and select comorbidities (standardized mean difference [SMD] ≥0.10). Post-IPTW, most variables were balanced (SMD < 0.01). Post-index total (Fab: $70,994; F(ab')₂: $55,324), medical ($69,162; $52,339), and inpatient costs ($49,466; $29,730) were higher among Fab than F(ab')₂ patients (all p < 0.05). After multivariable adjustment, the total (cost ratio [CR]: 0.83; 95% confidence interval [CI]: 0.70-0.98), inpatient (CR: 0.63; 95% CI: 0.51-0.79), and inpatient pharmacy costs (CR: 0.48; 95% CI: 0.33-0.68) were lower in the F(ab')₂ than Fab cohort.

Conclusions: Patients administered Fab had higher post-index total, inpatient, and inpatient pharmacy costs than patients administered F(ab')₂ AV.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.